<p>Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 获取免费报告）目前被覆盖的十三位分析师给予了 “买入” 的平均推荐，MarketBeat.com 报道。一位研究分析师对该股票给予了卖出推荐，十位分析师给予了买入推荐，另外两位给予了强烈买入推荐。在过去一年中更新了对该股票覆盖的经纪人中，平均一年目标价为 $11.6364。</p>
<p>获取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<ul>
<li>Neurogene 股票暴跌 44%：这家生物技术公司还有希望吗？</li>
</ul>
<p>几位股票研究分析师对 TSHA 股票发布了报告。Canaccord Genuity Group 将 Taysha Gene Therapies 的目标价从 $14.00 上调至 $17.00，并在 4 月 6 日的研究报告中给予该公司 “买入” 评级。Wall Street Zen 在周六的研究报告中将 Taysha Gene Therapies 的评级从 “持有” 下调至 “卖出”。Needham &amp; Company LLC 在 3 月 19 日的研究报告中将 Taysha Gene Therapies 的目标价从 $10.00 上调至 $12.00，并给予该公司 “买入” 评级。Chardan Capital 在 3 月 19 日的研究报告中重新发布了 “买入” 评级，并对 Taysha Gene Therapies 的股票设定了 $12.00 的目标价。最后，Truist Financial 在 3 月 25 日的研究报告中将 Taysha Gene Therapies 的评级提升至 “强烈买入”。</p>
<p><strong>查看我们对 TSHA 的最新股票分析</strong></p>
<h2>Taysha Gene Therapies 的内部买卖</h2>
<ul>
<li>3 只小盘股供您秋季购物清单参考</li>
</ul>
<p>在其他新闻中，内部人士 Sukumar Nagendran 于 4 月 10 日星期五出售了该公司 200,000 股股票。股票的平均售价为 $4.46，总价值为 $892,000.00。出售完成后，内部人士持有该公司 1,136,410 股股票，估值约为 $5,068,388.60。这代表其持股减少了 14.97%。该交易在向证券交易委员会提交的文件中披露，您可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士持有该公司 3.78% 的股份。</p>
<h2>机构投资者对 Taysha Gene Therapies 的看法</h2>
<p>几家对冲基金最近调整了对 TSHA 的持股。Marex Group plc 在第二季度购买了 Taysha Gene Therapies 的新股份，价值约 $29,000。E Fund Management Co. Ltd. 在第二季度购买了 Taysha Gene Therapies 的新股份，价值约 $31,000。Arrowpoint Investment Partners Singapore Pte. Ltd. 在第三季度购买了 Taysha Gene Therapies 的新股份，价值约 $40,000。Tower Research Capital LLC TRC 在第二季度将其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 现在拥有该公司 17,606 股股票，价值 $41,000，此前在此期间又购买了 10,742 股。最后，Caitong International Asset Management Co. Ltd 在第四季度将其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 现在拥有该公司 7,811 股股票，价值 $43,000，此前在此期间又购买了 4,607 股。对冲基金和其他机构投资者持有该公司 77.70% 的股份。</p>
<h2>Taysha Gene Therapies 的价格表现</h2>
<p>Taysha Gene Therapies 股票在周五开盘价为 $6.81。该股票的市值为 $19.6 亿，市盈率为 -17.92，贝塔值为 1.25。该公司的债务与股本比率为 0.20，流动比率为 12.23，速动比率为 12.23。Taysha Gene Therapies 的一年低点为 $2.06，一年高点为 $7.30。该公司的 50 日移动平均线为 $5.07，200 日移动平均线为 $4.93。</p>
<p>Taysha Gene Therapies（NASDAQ:TSHA - 获取免费报告）最后一次发布季度财报是在 5 月 6 日星期三。该公司报告每股收益（EPS）为 ($0.12)，低于市场共识预期的 ($0.10) 低了 ($0.02)。研究分析师平均预测 Taysha Gene Therapies 在本年度将发布 -0.44 的每股收益。</p>
<h2>关于 Taysha Gene Therapies</h2>
<p>（获取免费报告）</p>
<p>Taysha Gene Therapies, Inc NASDAQ: TSHA 是一家临床阶段的生物技术公司，专注于开发针对中枢神经系统罕见单基因疾病的基因疗法。该公司使用专有的腺病毒相关病毒（AAV）载体平台，设计新型的衣壳和调控元件，以优化治疗基因的递送和表达。其产品管线包括针对 GM2 神经节苷脂症（Tay–Sachs 和 Sandhoff 疾病）的 TSHA-102、针对 GM1 神经节苷脂症的 TSHA-101，以及针对芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及其他针对危及生命的儿童中枢神经系统疾病的早期候选药物。</p>
<p>Taysha Gene Therapies 成立于 2019 年，总部位于德克萨斯州达拉斯，于 2021 年 5 月完成首次公开募股。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，而不是 Taysha Gene Therapies</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 $1,000 在 Taysha Gene Therapies 吗？</h2>
<p>在您考虑 Taysha Gene Therapies 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Taysha Gene Therapies 并不在名单上。</p>
<p>虽然 Taysha Gene Therapies 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TSHA

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

<p>Taysha Gene Therapies, Inc.（纳斯达克代码：TSHA）获得了十三位分析师的平均 “买入” 推荐。一位分析师将其评为卖出，十位分析师评为买入，另外两位评为强力买入。平均一年目标价为 11.64 美元。最近的报告显示，Canaccord Genuity 和 Needham & Company 上调了目标价。内部人士 Sukumar Nagendran 出售了 200,000 股，减少了 14.97% 的持股比例。机构投资者持有 77.70% 的股份。TSHA 开盘价为 6.81 美元，市值为 19.6 亿美元，过去一年价格区间为 2.06 美元至 7.30 美元</p>

<p>Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average recommendation of &#34;Buy&#34; from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.6364.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 获取免费报告）目前被覆盖的十三位分析师给予了 “买入” 的平均推荐，MarketBeat.com 报道。一位研究分析师对该股票给予了卖出推荐，十位分析师给予了买入推荐，另外两位给予了强烈买入推荐。在过去一年中更新了对该股票覆盖的经纪人中，平均一年目标价为 $11.6364。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：这家生物技术公司还有希望吗？</li>
</ul>
</div><p>Several equities research analysts have issued reports on TSHA shares. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, April 6th. Wall Street Zen cut shares of Taysha Gene Therapies from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Needham &amp; Company LLC boosted their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 19th. Chardan Capital reissued a &#34;buy&#34; rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a &#34;strong-buy&#34; rating in a research report on Wednesday, March 25th.</p>
<div class="lb-trans"><p>几位股票研究分析师对 TSHA 股票发布了报告。Canaccord Genuity Group 将 Taysha Gene Therapies 的目标价从 $14.00 上调至 $17.00，并在 4 月 6 日的研究报告中给予该公司 “买入” 评级。Wall Street Zen 在周六的研究报告中将 Taysha Gene Therapies 的评级从 “持有” 下调至 “卖出”。Needham &amp; Company LLC 在 3 月 19 日的研究报告中将 Taysha Gene Therapies 的目标价从 $10.00 上调至 $12.00，并给予该公司 “买入” 评级。Chardan Capital 在 3 月 19 日的研究报告中重新发布了 “买入” 评级，并对 Taysha Gene Therapies 的股票设定了 $12.00 的目标价。最后，Truist Financial 在 3 月 25 日的研究报告中将 Taysha Gene Therapies 的评级提升至 “强烈买入”。</p>
</div><p><strong>View Our Latest Stock Analysis on TSHA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 TSHA 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的内部买卖</h2>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股供您秋季购物清单参考</li>
</ul>
</div><p>In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company's stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Sukumar Nagendran 于 4 月 10 日星期五出售了该公司 200,000 股股票。股票的平均售价为 $4.46，总价值为 $892,000.00。出售完成后，内部人士持有该公司 1,136,410 股股票，估值约为 $5,068,388.60。这代表其持股减少了 14.97%。该交易在向证券交易委员会提交的文件中披露，您可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士持有该公司 3.78% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>机构投资者对 Taysha Gene Therapies 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of TSHA. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $40,000. Tower Research Capital LLC TRC lifted its position in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after purchasing an additional 4,607 shares during the period. Hedge funds and other institutional investors own 77.70% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 TSHA 的持股。Marex Group plc 在第二季度购买了 Taysha Gene Therapies 的新股份，价值约 $29,000。E Fund Management Co. Ltd. 在第二季度购买了 Taysha Gene Therapies 的新股份，价值约 $31,000。Arrowpoint Investment Partners Singapore Pte. Ltd. 在第三季度购买了 Taysha Gene Therapies 的新股份，价值约 $40,000。Tower Research Capital LLC TRC 在第二季度将其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 现在拥有该公司 17,606 股股票，价值 $41,000，此前在此期间又购买了 10,742 股。最后，Caitong International Asset Management Co. Ltd 在第四季度将其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 现在拥有该公司 7,811 股股票，价值 $43,000，此前在此期间又购买了 4,607 股。对冲基金和其他机构投资者持有该公司 77.70% 的股份。</p>
</div><h2>Taysha Gene Therapies Price Performance</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的价格表现</h2>
</div><p>Taysha Gene Therapies stock opened at $6.81 on Friday. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -17.92 and a beta of 1.25. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. Taysha Gene Therapies has a 1 year low of $2.06 and a 1 year high of $7.30. The firm has a 50-day moving average of $5.07 and a two-hundred day moving average of $4.93.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 股票在周五开盘价为 $6.81。该股票的市值为 $19.6 亿，市盈率为 -17.92，贝塔值为 1.25。该公司的债务与股本比率为 0.20，流动比率为 12.23，速动比率为 12.23。Taysha Gene Therapies 的一年低点为 $2.06，一年高点为 $7.30。该公司的 50 日移动平均线为 $5.07，200 日移动平均线为 $4.93。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, research analysts forecast that Taysha Gene Therapies will post -0.44 earnings per share for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（NASDAQ:TSHA - 获取免费报告）最后一次发布季度财报是在 5 月 6 日星期三。该公司报告每股收益（EPS）为 ($0.12)，低于市场共识预期的 ($0.10) 低了 ($0.02)。研究分析师平均预测 Taysha Gene Therapies 在本年度将发布 -0.44 的每股收益。</p>
</div><h2>About Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>关于 Taysha Gene Therapies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc NASDAQ: TSHA 是一家临床阶段的生物技术公司，专注于开发针对中枢神经系统罕见单基因疾病的基因疗法。该公司使用专有的腺病毒相关病毒（AAV）载体平台，设计新型的衣壳和调控元件，以优化治疗基因的递送和表达。其产品管线包括针对 GM2 神经节苷脂症（Tay–Sachs 和 Sandhoff 疾病）的 TSHA-102、针对 GM1 神经节苷脂症的 TSHA-101，以及针对芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及其他针对危及生命的儿童中枢神经系统疾病的早期候选药物。</p>
</div><p>Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 成立于 2019 年，总部位于德克萨斯州达拉斯，于 2021 年 5 月完成首次公开募股。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Taysha Gene Therapies</li>
<li>巴菲特花了 60 年忽视科技，账单即将到来</li>
<li>对黄金感到兴奋但不确定其走势？试试这三种方法</li>
<li>美元处于三年低点：三家出口商悄然印钞</li>
<li>水务基础设施：为什么这个乏味的行业可能会变得令人兴奋</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 $1,000 在 Taysha Gene Therapies 吗？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Taysha Gene Therapies 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Taysha Gene Therapies 并不在名单上。</p>
</div><p>While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Taysha Gene Therapies 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Brokerages

Market Beat

Taysha Gene Therapies

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

Neurogene

Truist Financial

Marex

Taysha Gene Therapies, Inc.（纳斯达克股票代码：TSHA）被券商给予 “买入” 评级的平均推荐